• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

新型抗炎药3-甲酰氨基-7-甲基磺酰氨基-6-苯氧基-4H-1-苯并吡喃-4-酮的药理学研究。首次通讯:抗炎、镇痛及其他相关性质。

Pharmacological studies of the new antiinflammatory agent 3-formylamino-7-methylsulfonylamino-6-phenoxy-4H-1-benzopyran-4-o ne. 1st communication: antiinflammatory, analgesic and other related properties.

作者信息

Tanaka K, Shimotori T, Makino S, Aikawa Y, Inaba T, Yoshida C, Takano S

机构信息

Research Laboratories, Toyama Chemical Co., Ltd., Japan.

出版信息

Arzneimittelforschung. 1992 Jul;42(7):935-44.

PMID:1418059
Abstract

The antiinflammatory, analgesic and antipyretic activities of 3-formylamino-7-methylsulfonylamino-6-phenoxy-4H-1-benzopyran-4-on e (T-614, CAS 123663-49-0) were investigated in various animal models and compared with those of nimesulide, indomethacin and ibuprofen. The antiinflammatory potency of T-614 on carrageenin-induced paw edema, paper disk granuloma and established adjuvant arthritis was greater than that of ibuprofen, but slightly lower than those of nimesulide and indomethacin. In acute inflammatory models, unlike indomethacin, T-614 suppressed the edemas provoked by dextran and bromelain in rats, but its inhibitory action on ultraviolet erythema in guinea-pigs was weak. Although the analgesic activity of T-614 was hardly demonstrated in writhing tests in mice, its potency against the inflammatory pain such as Randall-Selitto test, adjuvant-induced hyperalgesia and antigen-induced arthritic pain in rats was superior to that of ibuprofen. Moreover, it had a potent analgesic effect on urate-induced synovitis in dogs. T-614 exerted a prompt and strong antipyretic effect in both yeast-induced febrile rats and lipopolysaccharide-induced febrile rabbits. T-614 had virtually no gastrointestinal ulcerogenic action and did not affect water and sodium excretion in rats. T-614 is a novel antiinflammatory compound with different pharmacological properties from that of the reference drugs.

摘要

在多种动物模型中研究了3-甲酰氨基-7-甲基磺酰氨基-6-苯氧基-4H-1-苯并吡喃-4-酮(T-614,CAS 123663-49-0)的抗炎、镇痛和解热活性,并与尼美舒利、吲哚美辛和布洛芬进行了比较。T-614对角叉菜胶诱导的爪肿胀、纸片肉芽肿和已形成的佐剂性关节炎的抗炎效力大于布洛芬,但略低于尼美舒利和吲哚美辛。在急性炎症模型中,与吲哚美辛不同,T-614可抑制大鼠右旋糖酐和菠萝蛋白酶引起的肿胀,但其对豚鼠紫外线红斑的抑制作用较弱。虽然在小鼠扭体试验中几乎未显示出T-614的镇痛活性,但其对大鼠炎症性疼痛(如Randall-Selitto试验、佐剂诱导的痛觉过敏和抗原诱导的关节炎疼痛)的效力优于布洛芬。此外,它对犬尿酸盐诱导的滑膜炎有强效镇痛作用。T-614对酵母诱导的发热大鼠和脂多糖诱导的发热兔均有迅速而强烈的解热作用。T-614几乎没有胃肠道致溃疡作用,且不影响大鼠的水和钠排泄。T-614是一种新型抗炎化合物,其药理特性与参比药物不同。

相似文献

1
Pharmacological studies of the new antiinflammatory agent 3-formylamino-7-methylsulfonylamino-6-phenoxy-4H-1-benzopyran-4-o ne. 1st communication: antiinflammatory, analgesic and other related properties.新型抗炎药3-甲酰氨基-7-甲基磺酰氨基-6-苯氧基-4H-1-苯并吡喃-4-酮的药理学研究。首次通讯:抗炎、镇痛及其他相关性质。
Arzneimittelforschung. 1992 Jul;42(7):935-44.
2
Pharmacological studies of the new antiinflammatory agent 3-formylamino-7-methylsulfonylamino-6-phenoxy-4'-1-benzopyran-4-o ne. 2nd communication: effect on the arachidonic acid cascades.
Arzneimittelforschung. 1992 Jul;42(7):945-50.
3
Anti-inflammatory, analgesic, and antipyretic effects and gastrointestinal toxicity of the new anti-inflammatory drug N-(3-[3-(piperidinylmethyl)phenoxy]propyl)-carbamoylmethylthio ]ethyl 1-(p-chlorobenzoyl) 5-methoxy-2-methyl-3-indolylacetate.新型抗炎药N-(3-[3-(哌啶基甲基)苯氧基]丙基)-氨甲酰甲基硫代]乙基1-(对氯苯甲酰基)-5-甲氧基-2-甲基-3-吲哚乙酸酯的抗炎、镇痛和解热作用及胃肠道毒性
Arzneimittelforschung. 1992 Jul;42(7):954-8.
4
The pharmacological profile of 2-(8-methyl-10,11-dihydro-11-oxodibenz[b,f]oxepin-2-yl)propionic acid (AD-1590), a new non-steroidal anti-inflammatory agent with potent antipyretic activity.2-(8-甲基-10,11-二氢-11-氧代二苯并[b,f]氧杂卓-2-基)丙酸(AD-1590)的药理学特征,一种具有强效解热活性的新型非甾体抗炎药。
Arzneimittelforschung. 1983;33(11):1555-69.
5
Pharmacological properties of 2-[4-(2-thiazolyloxy)-phenyl]-propionic acid (480156-S), a new non-steroidal antiinflammatory agent.新型非甾体抗炎药2-[4-(2-噻唑氧基)-苯基]-丙酸(480156-S)的药理特性
Arzneimittelforschung. 1984;34(3):280-6.
6
Pharmacological properties of the new non-steroidal anti-inflammatory agent etodolac.新型非甾体抗炎药依托度酸的药理特性
Arzneimittelforschung. 1991 Mar;41(3):228-35.
7
Pharmacological study of the new nonsteroidal antiinflammatory agent 4'-acetamidophenyl-2-(5'-p-toluyl-1'-methylpyrrole)acetate.新型非甾体抗炎药4'-乙酰氨基苯基-2-(5'-对甲苯基-1'-甲基吡咯)乙酸酯的药理学研究
Arzneimittelforschung. 1988 Apr;38(4):546-51.
8
Pharmacological properties of the novel non-steroidal antiinflammatory agent N-methoxy-3-(3,5-di-tert-butyl-4-hydroxybenzylidene)pyrrolidin-2 -one.
Arzneimittelforschung. 1987 Aug;37(8):930-6.
9
Pharmacological properties of droxicam, a new non-steroidal anti-inflammatory agent.新型非甾体抗炎药屈昔康的药理特性
Methods Find Exp Clin Pharmacol. 1986 Jul;8(7):407-22.
10
The pharmacological properties of fenbufen. A review.联苯乙酸的药理特性。综述。
Arzneimittelforschung. 1980;30(4A):716-21.

引用本文的文献

1
Macrophage migration inhibitory factor as a therapeutic target in neuro-oncology: A review.巨噬细胞迁移抑制因子作为神经肿瘤学的治疗靶点:综述
Neurooncol Adv. 2024 Aug 10;6(1):vdae142. doi: 10.1093/noajnl/vdae142. eCollection 2024 Jan-Dec.
2
Research progress on the clinical application and mechanism of iguratimod in the treatment of autoimmune diseases and rheumatic diseases.依那西普治疗类风湿关节炎的临床疗效及安全性的Meta 分析
Front Immunol. 2023 Sep 21;14:1150661. doi: 10.3389/fimmu.2023.1150661. eCollection 2023.
3
Iguratimod efficacy in palindromic rheumatism treatment.
依阁来特莫德治疗复发性风湿症的疗效。
Immun Inflamm Dis. 2023 Jun;11(6):e932. doi: 10.1002/iid3.932.
4
Iguratimod Alleviates Myocardial Ischemia/Reperfusion Injury Through Inhibiting Inflammatory Response Induced by Cardiac Fibroblast Pyroptosis via COX2/NLRP3 Signaling Pathway.艾拉莫德通过COX2/NLRP3信号通路抑制心脏成纤维细胞焦亡诱导的炎症反应减轻心肌缺血/再灌注损伤。
Front Cell Dev Biol. 2021 Oct 25;9:746317. doi: 10.3389/fcell.2021.746317. eCollection 2021.
5
Iguratimod promotes transformation of mononuclear macrophages in elderly patients with rheumatoid arthritis by nuclear factor-κB pathway.艾拉莫德通过核因子κB途径促进老年类风湿关节炎患者单核巨噬细胞的转化。
World J Clin Cases. 2021 Apr 6;9(10):2181-2191. doi: 10.12998/wjcc.v9.i10.2181.
6
Molecular mechanisms and clinical studies of iguratimod for the treatment of ankylosing spondylitis.艾拉莫德治疗强直性脊柱炎的分子机制及临床研究
Clin Rheumatol. 2021 Jan;40(1):25-32. doi: 10.1007/s10067-020-05207-z. Epub 2020 Jun 6.
7
Clinical effectiveness of iguratimod based on real-world data of patients with rheumatoid arthritis.基于类风湿关节炎患者真实世界数据的艾拉莫德临床疗效
Clin Rheumatol. 2021 Jan;40(1):123-132. doi: 10.1007/s10067-020-05208-y. Epub 2020 Jun 6.
8
Iguratimod as a New Drug for Rheumatoid Arthritis: Current Landscape.艾拉莫德作为类风湿关节炎的新药:现状
Front Pharmacol. 2020 Feb 26;11:73. doi: 10.3389/fphar.2020.00073. eCollection 2020.
9
Iguratimod: a valuable remedy from the Asia Pacific region for ameliorating autoimmune diseases and protecting bone physiology.艾拉莫德:一种来自亚太地区的用于改善自身免疫性疾病和保护骨骼生理功能的珍贵药物。
Bone Res. 2019 Sep 3;7:27. doi: 10.1038/s41413-019-0067-6. eCollection 2019.
10
A randomized phase I study to evaluate the safety, tolerability, pharmacokinetics and food-effect of Iguratimod in healthy adult volunteers.一项评估艾拉莫德在健康成年志愿者中的安全性、耐受性、药代动力学及食物影响的随机I期研究。
Eur J Clin Pharmacol. 2018 Jan;74(1):69-77. doi: 10.1007/s00228-017-2342-z. Epub 2017 Oct 19.